AURA BIOSCIENCES INC (AURA)
Health Care · Oncolytic immunotherapy · NASDAQ
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving organ function.
What AURA BIOSCIENCES INC does
Aura Biosciences is a clinical-stage biopharmaceutical company developing VDC (Virus-Directed Cytolytic) therapy platform and its lead candidate bel-sar, an investigational oncolytic immunotherapy designed to treat choroidal melanoma and other solid tumors. The company is currently conducting clinical trials for bel-sar in early choroidal melanoma and expanding into additional oncology indications including bladder cancer and choroidal metastases. Aura has generated no product revenue to date and is primarily advancing its research and development programs toward regulatory approval.
Themes: oncology, ocular oncology, targeted cancer therapy, drug conjugates, clinical-stage biopharma
Fundamentals
- Price$7.80 as of 2026-08-21 close
- Market cap$809M as of 2026-08-21
- 1-year return+20.6% 2025-08-21 close $6.47 → 2026-08-21 close $7.80
- P/En/a earnings data not available
- ROE-78.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.41 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How AURA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AURA BIOSCIENCES INC looks technically
AURA BIOSCIENCES INC (AURA) is trading 20.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 85 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 18.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 20.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +20.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.14 | $7.14 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.49 | $6.49 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 6.8. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 85 trading days ago — a "golden cross", a bullish long-term signal | 85 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.96 to $8.37) — its "stochastic" reading is 60 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 59.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 24 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.54 | $9.54 |
|---|---|---|
| From the 52-week high | it is 18.2% below its 52-week high (its highest price of the past year) | -18.2% |
| Above the 52-week low | it is 64.9% above its 52-week low (its lowest price of the past year) | +64.9% |
| Below the 52-week high | it is 18.2% below its highest point of the past year | 18.2% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $25.94 (set on 2021-11-16) | $25.94 |
| Given back of the 52-week move | over the past year its closes ranged ($4.97 to $8.90), and it has given back roughly a quarter of its rise from last year’s low — 28% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.35 to $6.47. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.0% |
| From the all-time high | it is 69.9% below its all-time high | -69.9% |
| Nearest price level | it is trading 1.3% above a support level at $7.70 — a price it turned at three times since 2025-03-03, most recently on 2026-04-22. Since 2024-08-21 it has 12 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $4.34 (set on 2025-05-15) | $4.34 |
| Above the all-time low | it is 79.5% above its all-time low | +79.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4486 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4486 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.77 and $8.28 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.77 – $7.52 – $8.28 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 2.9 daily ranges above its 200-day average price (20.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 11.7% since the prior reading | -11.7% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 3.4% gap down opened on 2026-08-12 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 3 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.6 percentage points (the stock gained 11.0% while the market gained 2.3%) | +8.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.1 percentage points (the stock gained 2.0% while the market gained 3.1%) | -1.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 33.1 percentage points (the stock gained 44.2% while the market gained 11.1%) | +33.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 0.1 percentage points (the stock gained 20.6% while the market gained 20.5%) | +0.1% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +0.2% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.17 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +8.8% |
|---|
Price levels it has turned at before
AURA last closed at $7.80 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.70 | Support | 1.3% below the last close | turned there three times · 2025-03-03 to 2026-04-22 |
| $7.93 | Resistance | 1.7% above the last close | turned there three times · 2024-12-23 to 2026-07-06 |
| $7.55 | Support | 3.2% below the last close | turned there four times · 2025-01-29 to 2025-07-28 |
| $8.19 | Resistance | 5.0% above the last close | turned there five times · 2024-08-29 to 2025-02-14 |
| $7.33 | Support | 6.1% below the last close | turned there four times · 2024-09-03 to 2026-07-27 |
| $8.65 | Resistance | 11.0% above the last close | turned there twice · 2024-11-21 to 2025-01-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $6.80.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · trendless / choppy (low ADX) · Analyst price target recently CUT · beating the market · Printed a doji candle · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$16.60 range $12.00 – $23.00; median $15.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of net losses with no product revenue and a high risk of failure in clinical development, which raises concerns about long-term financial viability.","Significant reliance on the successful clinical and regulatory advancement of its lead candidate, bel-sar, and the proprietary VDC platform.","Substantial capital requirements for ongoing research, development, and future commercialization, necessitating potential future equity or debt financing."]
What changed in the latest 10-Q
AI-assisted comparison of AURA's 10-Q filed 2026-05-11 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Added specification of early choroidal melanoma as '(defined as small choroidal melanoma and/or indeterminate lesions)' in newer filing (2026-05-11)
- Added mention of 'cancers of the ocular surface' being evaluated in newer filing alongside other indications
- Added reference to Phase 1 proof-of-concept trial initiation in cancers of the ocular surface in newer filing
- Added reference to announcement of positive Phase 1 NMIBC data 'In 2025' in newer filing (2026-05-11)
- Added reference to ongoing Phase 1b/2 trial in NMIBC in newer filing
- Added disclosure of capital raise on May 5, 2026, with 46,099,650 shares of common stock issued and aggregate of $797.8 million raised from inception through May 5, 2026 in newer filing
- Removed:
- Removed specific enrollment timeline statement 'We believe enrollment for this Phase 3 trial may be completed in 2026, and we expect to provide top-line data readout for the 15-month primary endpoint in the fourth quarter of 2027' from older filing (2025-11-13)
- Removed 'metastases of the choroid' and replaced with 'metastases to the choroid' (wording change)
- Removed extensive details about Phase 2 trial initiation in metastases to the choroid from breast and lung cancer with protocol amendments
- Removed expectation statement 'We expect early proof-of-concept data from this trial in 2026' regarding metastases trial
- Removed details on ocular surface cancers incidence rate (35,000 patients per year in U.S. and Europe) and plan for initial data in 2026
- Removed descriptor 'early clinical development' for bladder cancer, changed to just 'in clinical development'
- Removed phrase 'the majority of cases are diagnosed early as' and changed to 'and the majority of cases are diagnosed early as'
- Removed detailed descriptions of Phase 1b/2 trial design including immune ablative approach and multimodal neoadjuvant design with TURBT details
- Reworded:
- Changed 'we plan to expand clinical development' to 'we are expanding clinical development' regarding ocular surface indications (newer filing emphasizes ongoing action)
- Changed description from 'early clinical development in bladder cancer' to 'in clinical development' in newer filing (removed 'early' descriptor)
- Changed 'In March 2025, we announced positive data' to 'In 2025, we announced positive data' in newer filing (less specific timing)
- Simplified description of metastases indication from detailed trial specifics to 'We continue to enroll patients in an ongoing Phase 2 clinical trial in metastases to the choroid'
- Notes:
- Newer filing text appears truncated at end ('On May 5, 2026, we issued and sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon the underwriters' exercise in full of their option to purc'), limiting full comparison of capital raise details
- Older filing text also appears truncated mid-sentence regarding TURBT and trial design details, limiting full assessment of removed content
Risk Factors
- Added:
- Newer filing (2026-05-11) shows Item 1A Risk Factors on page 30, compared to page 31 in older filing (2025-11-13)
- Newer filing shows financial statements as of and for three months ended March 31, 2026 and 2025
- Older filing shows financial statements as of and for nine months ended September 30, 2025 and 2024
- Newer filing Balance Sheet dated March 31, 2026 and December 31, 2025; older filing dated September 30, 2025 and December 31, 2024
- Newer filing shows cash and cash equivalents of $84,793k (March 31, 2026) vs. $47,553k (September 30, 2025 in older filing)
- Newer filing shows marketable securities of $29,940k (March 31, 2026) vs. $114,313k (September 30, 2025 in older filing)
- Newer filing shows total assets of $137,677k (March 31, 2026) vs. $190,024k (September 30, 2025 in older filing)
- Newer filing Statements of Operations cover three months ended March 31, 2026 and 2025; older filing covers three and nine months ended September 30, 2025 and 2024
- Newer filing shows R&D expenses of $27,960k (Q1 2026) vs. $22,178k (Q3 2025 in older filing)
- Newer filing shows net loss of $(33,685)k (Q1 2026) vs. $(26,130)k (Q3 2025 in older filing)
- Newer filing Statements of Stockholders' Equity shows balance as of March 31, 2026 with 64,150,468 shares outstanding vs. September 30, 2025 balance in older filing with 62,985,569 shares
- Newer filing shows accumulated deficit of $(514,103)k (March 31, 2026) vs. $(454,859)k (September 30, 2025 in older filing)
- Newer filing shows accumulated other comprehensive loss of $(207)k (March 31, 2026) vs. accumulated other comprehensive income of $69k (September 30, 2025 in older filing)
- Newer filing Cash Flow Statement covers nine months ended March 31 for 2026 and 2025; older filing covers nine months ended September 30 for 2025 and 2024
- Removed:
- Older filing nine-month comparative results for 2025 and 2024 not presented in newer filing
- Older filing June 30, 2025 interim period data in Stockholders' Equity table not in newer filing
- Older filing June 30, 2024 interim period data in Stockholders' Equity table not in newer filing
- Older filing references to ATM facility equity issuance ($3,360k net in Q2 2025) not in newer filing
- Reworded:
- Newer filing Item 1A page reference changed from 31 to 30
- Newer filing shows 'Other income (expense)' line item with value of $2k (Q1 2026) vs. 'Other expense' of $(13)k (Q3 2025 in older filing)
- Newer filing accumulated other comprehensive section changed from 'income' to 'loss' label reflecting negative balance
- Notes:
- The two filings report on different fiscal periods (Q1 2026 vs. Q3 2025), making direct operational comparisons between periods inherently different
- Newer filing is 10-Q for quarter ended March 31, 2026; older filing is 10-Q for quarter ended September 30, 2025
- Financial statement data presented reflects different reporting dates and cannot be directly compared as period-over-period changes without considering the time gap
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($82330) — 1 selling insider
- Last 180 days0 buys · 3 sells ($39M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AURA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AURA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,668,807
- Reported value $31,234,320
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AURA had 6,358,049 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AURA had 6.13% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.46 days to cover at the same settlement.
- Reported short interest (shares) 6,358,049
- Short interest (% of shares outstanding) 6.13%
- Prior settlement (shares) 5,608,945
- Reported change 13.36%
- Days to cover (reported) 18.46
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Immunocore (IMCR)
- Castle Biosciences (CSTL)
- Iovance Biotherapeutics (IOVA)
- Blueprint Medicines (BPMC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AURA vs…
AURA BIOSCIENCES INC is found in…
Frequently asked questions
What does AURA BIOSCIENCES INC (AURA) do?
Aura Biosciences is a clinical-stage biopharmaceutical company developing VDC (Virus-Directed Cytolytic) therapy platform and its lead candidate bel-sar, an investigational oncolytic immunotherapy designed to treat choroidal melanoma and other solid tumors. The company is currently conducting clinical trials for bel-sar in early choroidal melanoma and expanding into additional oncology indications including bladder cancer and choroidal metastases.
What sector is AURA BIOSCIENCES INC (AURA) in?
AURA BIOSCIENCES INC (AURA) is classified in the Health Care sector. Its industry is Oncolytic immunotherapy. It trades on NASDAQ.
Who are AURA BIOSCIENCES INC's (AURA) competitors?
Notable peers of AURA BIOSCIENCES INC (AURA) include Immunocore, Castle Biosciences, Iovance Biotherapeutics and Blueprint Medicines. This peer set is informational only — not financial advice.
Is AURA BIOSCIENCES INC (AURA) overbought or oversold right now?
AURA BIOSCIENCES INC (AURA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AURA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.